Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women with strongly ER-positive/HER2-negative tumors.
Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates.
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and monitor toxicities.
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses managing toxicities of immunotherapy, including neurotoxicity, and treating beyond acute adverse events.
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.
For more information about this ongoing trial, visit clinicaltrials.gov
ClinicalTrials.gov ID: NCT03132636
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib and trametinib; and neoadjuvant ipilimumab and nivolumab therapy.
